Hepatitis C Nucleic Acid Test Positive (NAT+) Solid Organ Consent Rates Are Highest in Patients Listed for Liver Transplant and With an English Language Preference

IF 1.9 4区医学 Q2 SURGERY

Clinical Transplantation Pub Date : 2025-06-08 DOI:10.1111/ctr.70186

Sachiko M. Oshima, Alice Parish, Jacqueline B. Henson, Mariya Samoylova, Donna Niedzwiecki, Lisa McElroy, Lindsay King, Julius M. Wilder, Kara Wegermann

{"title":"Hepatitis C Nucleic Acid Test Positive (NAT+) Solid Organ Consent Rates Are Highest in Patients Listed for Liver Transplant and With an English Language Preference","authors":"Sachiko M. Oshima, Alice Parish, Jacqueline B. Henson, Mariya Samoylova, Donna Niedzwiecki, Lisa McElroy, Lindsay King, Julius M. Wilder, Kara Wegermann","doi":"10.1111/ctr.70186","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Transplantation of hepatitis C virus (HCV) nucleic acid (NAT) positive organs is associated with shorter time to transplant and decreased risk of death on the waiting list. Treatment for HCV post-transplant is well-tolerated, successful, and leads to similar transplant outcomes to patients transplanted with HCV NAT− organs. Despite these outcomes, not all patients consent to receive HCV NAT+ organs, and factors associated with consent are not well-known.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This retrospective single-center study of adult patients listed for heart, liver, lung, and kidney transplant aimed to determine whether sociodemographic and organ-specific disparities exist in consent for HCV NAT+ donor organs.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of 2788 transplant candidates, 44% (<i>N</i> = 1229) consented to receive an HCV NAT+ organ. Patients who designated English as their preferred language were more likely to consent compared to a non-English preference (45% vs. 19%, <i>p</i> < 0.001). Consent rates were highest amongst patients listed for liver transplantation compared to kidney, heart, and lung transplants (67%, <i>N</i> = 319 vs. 42%, <i>N</i> = 602 vs. 38%, <i>N</i> = 159 vs. 32%, <i>N</i> = 149; <i>p</i> < 0.001).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Overall, more efforts are needed to ensure that all patients who may benefit from consenting for HCV NAT+ organs are appropriately educated in their language of choice on the risks and benefits.</p>\n </section>\n </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 6","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70186","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Transplantation of hepatitis C virus (HCV) nucleic acid (NAT) positive organs is associated with shorter time to transplant and decreased risk of death on the waiting list. Treatment for HCV post-transplant is well-tolerated, successful, and leads to similar transplant outcomes to patients transplanted with HCV NAT− organs. Despite these outcomes, not all patients consent to receive HCV NAT+ organs, and factors associated with consent are not well-known.

Methods

This retrospective single-center study of adult patients listed for heart, liver, lung, and kidney transplant aimed to determine whether sociodemographic and organ-specific disparities exist in consent for HCV NAT+ donor organs.

Results

Of 2788 transplant candidates, 44% (N = 1229) consented to receive an HCV NAT+ organ. Patients who designated English as their preferred language were more likely to consent compared to a non-English preference (45% vs. 19%, p < 0.001). Consent rates were highest amongst patients listed for liver transplantation compared to kidney, heart, and lung transplants (67%, N = 319 vs. 42%, N = 602 vs. 38%, N = 159 vs. 32%, N = 149; p < 0.001).

Conclusions

Overall, more efforts are needed to ensure that all patients who may benefit from consenting for HCV NAT+ organs are appropriately educated in their language of choice on the risks and benefits.

查看原文本刊更多论文

丙型肝炎核酸检测阳性（NAT+）的患者在接受肝移植和英语语言偏好的患者中，实体器官同意率最高

背景丙型肝炎病毒（HCV）核酸（NAT）阳性器官移植与移植时间缩短和等待死亡风险降低相关。HCV移植后的治疗耐受性良好，成功，并且与移植HCV NAT−器官的患者的移植结果相似。尽管有这些结果，但并非所有患者都同意接受HCV NAT+器官，并且与同意相关的因素尚不清楚。方法本回顾性单中心研究纳入了接受心、肝、肺和肾移植的成年患者，旨在确定在同意接受HCV NAT+供体器官方面是否存在社会人口统计学和器官特异性差异。结果在2788例移植候选者中，44% （N = 1229）同意接受HCV NAT+器官。指定英语为首选语言的患者比非英语首选语言的患者更有可能同意(45%对19%，p <；0.001)。与肾、心、肺移植相比，肝移植患者的同意率最高(67%,N = 319 vs. 42%, N = 602 vs. 38%, N = 159 vs. 32%, N = 149；p & lt;0.001)。总的来说，需要做出更多的努力，以确保所有可能从同意移植HCV NAT+器官中受益的患者都能以他们选择的语言接受有关风险和益处的适当教育。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Transplantation 医学-外科

CiteScore

3.70

自引率

4.80%

发文量

286

审稿时长

2 months

期刊介绍： Clinical Transplantation: The Journal of Clinical and Translational Research aims to serve as a channel of rapid communication for all those involved in the care of patients who require, or have had, organ or tissue transplants, including: kidney, intestine, liver, pancreas, islets, heart, heart valves, lung, bone marrow, cornea, skin, bone, and cartilage, viable or stored. Published monthly, Clinical Transplantation’s scope is focused on the complete spectrum of present transplant therapies, as well as also those that are experimental or may become possible in future. Topics include: Immunology and immunosuppression; Patient preparation; Social, ethical, and psychological issues; Complications, short- and long-term results; Artificial organs; Donation and preservation of organ and tissue; Translational studies; Advances in tissue typing; Updates on transplant pathology;. Clinical and translational studies are particularly welcome, as well as focused reviews. Full-length papers and short communications are invited. Clinical reviews are encouraged, as well as seminal papers in basic science which might lead to immediate clinical application. Prominence is regularly given to the results of cooperative surveys conducted by the organ and tissue transplant registries. Clinical Transplantation: The Journal of Clinical and Translational Research is essential reading for clinicians and researchers in the diverse field of transplantation: surgeons; clinical immunologists; cryobiologists; hematologists; gastroenterologists; hepatologists; pulmonologists; nephrologists; cardiologists; and endocrinologists. It will also be of interest to sociologists, psychologists, research workers, and to all health professionals whose combined efforts will improve the prognosis of transplant recipients.